Last Updated on eMC 19-07-2017 View medicine  | GlaxoSmithKline UK Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Reasons for adding or updating:

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Reasons for adding or updating:

  • Change to section 6 - date of revision
  • Change to other sources of information section

Reasons for adding or updating:

  • Change to section 6 - date of revision
  • Change to section 4 - possible side effects

Reasons for adding or updating:

  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Reasons for adding or updating:

  • Previous version of PIL reinstated

Reasons for adding or updating:

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Reasons for adding or updating:

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Reasons for adding or updating:

  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Reasons for adding or updating:

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Reasons for adding or updating:

  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects

Reasons for adding or updating:

  • Change to section 4 - how to report a side effect
  • Change to section 5 - how to store
  • Change to section 6 - date of revision
  • Correction of spelling/typing errors

Reasons for adding or updating:

  • New PIL for new product